Content
Search
Navigation
Sitemap
About us
Pipeline & science
Overview
Obesity
Acute Ischemic Stroke (AIS)
Hypertension
Our expertise
Overview
Our strategic partners
Global opportunities
Join us
Press releases
Contact
简体中文
Search
简体中文
Navigation
Press releases
19 Aug 2024
JIXING Announces the Successful Completion of Patient Enrollment in Phase 3 Clinical Study of LNZ100 for the Treatment of Presbyopia in China
Read article
13 Aug 2024
LENZ Therapeutics Announces Submission of New Drug Application to U.S. Food and Drug Administration for LNZ100 for the Treatment of Presbyopia
Read article
14 May 2024
Cytokinetics Announces Primary Results From SEQUOIA-HCM Presented in Late Breaking Clinical Trial Session at the European Society of Cardiology Heart Failure 2024 Congress and Published in the New England Journal of Medicine
Read article
08 Apr 2024
Cytokinetics Presents Additional 48-Week Data From FOREST-HCM, the Open Label Extension Clinical Study of Aficamten, at The American College of Cardiology 73ʳᵈ Annual Scientific Session
Read article
05 Apr 2024
LENZ Therapeutics Announces Positive Topline Data from Phase 3 CLARITY Presbyopia Trials
Read article
13 Mar 2024
JIXING Announces the CTA Approval of China Cohort of ACACIA-HCM, a Pivotal Phase 3 Clinical Trial of Aficamten in Patients With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy
Read article
Load more
